The American Journal of Managed Care®
Call for Papers
The American Journal of Managed Care® (AJMC®) is continually seeking submissions for the regular issue, as well as an annual theme issue on health information technology and other topics. AJMC’s editorial coverage interests also include articles in a variety of therapeutic categories to help translate clinical discoveries into better health outcomes and accelerate the implementation of proven innovations and technologies.
We seek original research and informed commentary covering a wide range of managed care topics:
- Disease areas (cancer, diabetes, cardiovascular complications, multiple sclerosis, rheumatoid arthritis, infectious disease, other)
- The evolving role of quality measures
- Effects of health care policy reform
- Obstacles and best practices in providing access to the entire continuum of care
- Improving patient adherence
- Impact of care coordination on health outcomes
- Successes and challenges of various care delivery models
- Methodologies for provider and payer accountability
- Innovative partnerships between payers, providers, and manufacturers
- Effects of changing capitation and reimbursement models on health care delivery
- Cost of new therapeutic agents and their impact on utilization
- Comparative effectiveness research and methodologies
- Methods to identify and eliminate low-value care
Click here to access the submission guidelines for details on formatting and other requirements. Due to space restrictions, please limit your manuscript as outlined in the Manuscript Categories section. The final decision regarding a paper’s acceptance will be made by the editors; each accepted paper will be peer reviewed.
Please submit all manuscripts through AJMC’s online submission system at http://mc.manuscriptcentral.com/ajmc
If you have questions or wish to speak to an editor, please email Christina Mattina at cmattina@ajmc.com.
Health Information Technology
AJMC is issuing a call for papers for the 14th Annual Health Information Technology (IT)-focused issue, with a publication date of January 2025. Amid rapid advancements in health IT and AI, there is a growing need to explore the implications for health care delivery and management across a variety of clinical settings, payment models, and patient populations. Despite the increased uptake of virtual care modalities spurred by the COVID-19 pandemic, use of health IT in the postpandemic landscape is not uniform, and there are opportunities to improve the user experience. More work remains to be done in encouraging interoperability, addressing privacy and security concerns, and ensuring that IT and AI tools contribute to goals of health equity rather than exacerbating existing disparities.
Click here to view the Call for Papers for this issue.
Obesity Treatment
AJMC is issuing a call for papers on obesity treatment. These papers, in addition to the journal’s regular content, will be published throughout upcoming issues of the journal.
Obesity is a serious, progressive, chronic disease associated with a spectrum of complications and poor outcomes. Until recently, FDA-approved medications for the long-term treatment of obesity in the general adult population had not demonstrated the ability to achieve guideline-recommended levels of body weight loss. The recent introduction of highly effective anti-obesity medications has provoked a sea change in the treatment of obesity, with new guidelines now recommending use of these novel therapies for the long-term treatment of obesity. However, these clinical advances also carry questions of how to ensure patients can access and pay for these therapies.
Click here to view the Call for Papers.
Paying for Curative Therapies
AJMC is issuing a call for papers on paying for curative therapies. These papers, in addition to the journal’s regular content, will be published throughout the upcoming issues of the journal.
Revolutionary medical treatments including cell and gene therapies hold the potential to cure or significantly alleviate serious disorders in disease states ranging from hematology to neurology to ophthalmology. Their introduction has brought new hope to patients and families facing these diseases but simultaneously poses significant challenges from the payer perspective—with some incurring costs of millions of dollars per course of therapy. The introduction of high-cost curative therapies can disrupt budgets and upend traditional reimbursement models for payers including government programs, insurance companies, and managed care organizations.
Click here to view the Call for Papers.
